Form 4: Elicio Therapeutics Chief Scientific Officer Exercises Stock Options
SEC Filing
Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, exercised stock options at a price of $4.41 on December 16, 2024.
Summary
- Peter DeMuth, the Chief Scientific Officer of Elicio Therapeutics, Inc. (ELTX), filed a Form 4 on December 18, 2024.
- The form reports a transaction that occurred on December 16, 2024, where DeMuth exercised stock options to acquire 381 shares of common stock at a price of $4.41 per share.
- The stock options were granted with a vesting schedule that began on December 18, 2015, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option exercises, indicating a neutral sentiment.
Industry Context
This is a routine disclosure related to executive compensation and stock option exercises, common in publicly traded companies.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| December 18, 2015 | Initial grant date of the stock options with 25% vesting on the first anniversary. |
| December 16, 2024 | Date of transaction: Peter DeMuth exercised stock options. |
| December 18, 2024 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.